These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12363257)

  • 1. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization for aldose reductase in diabetic lenses.
    Akagi Y; Kador PF; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1987 Jan; 28(1):163-7. PubMed ID: 3100473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).
    Asano T; Saito Y; Kawakami M; Yamada N; Sekino H; Hasegawa S;
    J Diabetes Complications; 2004; 18(6):336-42. PubMed ID: 15531183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
    Madhu SV; Verma NP; Goel A; Kapoor VK
    J Assoc Physicians India; 1992 Oct; 40(10):679-81. PubMed ID: 1307356
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF; Wyman M; Oates PJ
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of aldose reductase by nonenzymatic glycosylation.
    Srivastava SK; Ansari NH; Bhatnagar A; Hair G; Liu S; Das B
    Prog Clin Biol Res; 1989; 304():171-84. PubMed ID: 2506561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment.
    Meyer LA; Ubels JL; Edelhauser HF
    Invest Ophthalmol Vis Sci; 1988 Jun; 29(6):940-8. PubMed ID: 2967259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correction of diabetic neuropathies using aldose reductase inhibitors and pikamilon].
    Kuchmerovskaia TM; Parkhomets PK; Donchenko GV; Obrosova IG; Klimenko AP; Kuchmerovskiĭ NA; Pakirbaeva LV; Efimov AS
    Vopr Med Khim; 1998; 44(6):559-64. PubMed ID: 10599142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic complications in the cornea.
    Ljubimov AV
    Vision Res; 2017 Oct; 139():138-152. PubMed ID: 28404521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study.
    Fujishima H; Shimazaki J; Yagi Y; Tsubota K
    Cornea; 1996 Jul; 15(4):368-75. PubMed ID: 8776562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aldose reductase inhibitory capacity of Sorbus domestica fruit extracts depends on their phenolic content and may be useful for the control of diabetic complications.
    Termentzi A; Alexiou P; Demopoulos VJ; Kokkalou E
    Pharmazie; 2008 Sep; 63(9):693-6. PubMed ID: 18819524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition.
    Hotta N
    Nagoya J Med Sci; 1997 Nov; 60(3-4):89-100. PubMed ID: 9481088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
    Bosquet F; Grimaldi A
    Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.